Literature DB >> 17040699

Malaria vaccine development: current status.

H D Engers, T Godal.   

Abstract

The development of an effective malaria vaccine represents one of the most important approaches that would provide a cost-effective intervention for addition to currently available malaria control strategies. Here, Howard Engers and Tore Godal review recent advances. Over the past decade there has been considerable progress in the understanding of immune mechanisms involved in conferring protection to malaria and in the identification of vaccine candidate antigens and their genes. Several new vaccines have entered Phase I/II trials recently, new adjuvants have been developed for human use and new approaches, such as DNA vaccines and structural modification of antigens to circumvent some of the strategies the parasite uses to avoid the immune response, are being applied. Thus, from the TDR perspective, global malaria vaccine development is entering a crucial period with unprecedented opportunities.

Entities:  

Year:  1998        PMID: 17040699     DOI: 10.1016/s0169-4758(97)01184-8

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  16 in total

1.  Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen, II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119.

Authors:  O Garraud; A Diouf; I Holm; R Perraut; S Longacre
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

Review 2.  Current status of malaria and potential for control.

Authors:  R S Phillips
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

3.  Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Authors:  H Hisaeda; A W Stowers; T Tsuboi; W E Collins; J S Sattabongkot; N Suwanabun; M Torii; D C Kaslow
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

4.  Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.

Authors:  F Pöltl-Frank; R Zurbriggen; A Helg; F Stuart; J Robinson; R Glück; G Pluschke
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

5.  A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains.

Authors:  J M Burns; C C Belk; P D Dunn
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

6.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

7.  IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil.

Authors:  Cristiane G Morais; Irene S Soares; Luzia H Carvalho; Cor Jesus F Fontes; Antoniana U Krettli; Erika Martins Braga
Journal:  Parasitol Res       Date:  2005-03-10       Impact factor: 2.289

8.  Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.

Authors:  Arnoldo Barbosa; Denise Naniche; John J Aponte; M Nelia Manaca; Inacio Mandomando; Pedro Aide; Jahit Sacarlal; Montse Renom; Sarah Lafuente; W Ripley Ballou; Pedro L Alonso
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

Review 9.  Immunity to liver stage malaria: considerations for vaccine design.

Authors:  Andrew W Taylor-Robinson
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Protective immunization with a novel membrane protein of Plasmodium yoelii-infected erythrocytes.

Authors:  J M Burns; E K Adeeku; P D Dunn
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.